VJOncology is committed to improving our service to you

ESMO 2016 | NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer patients

VJOncology is committed to improving our service to you

Nicoletta Colombo

Nicoletta Colombo, MD, PhD from the European Institute of Oncology (IEO), Milan, Italy gives an overview of the Phase III ENGOT-OV16/NOVA trial of niraparib versus placebo in platinum-sensitive ovarian cancer patients (NCT01847274). Patients received either placebo or the PARP inhibitor, niraparib. Further, the trial looked at two different patient populations; one with a germline BRCA mutation (gBRCA cohort) and one without a germline BRCA mutation (non-gBRCA cohort). The trial showed a significant progression-free survival (PFS) advantage for patients in the gBRCA cohort (21 vs 5.5 months). Furthermore, there was a significant advantage in terms of PFS in the non-gBRCA cohort (9.3 vs 3.9 months). This shows that the PARP inhibitor niraparib can be used effectively for both groups of patients. Patients in the non-gBRCA cohort were also tested for homologous recombination deficiency (HRD) to determine within the sub-population, which individuals would have the best response to niraparib.
Recorded at the European Society of Medical Oncology (ESMO) 2016 Congress, held in Copenhagen, Denmark.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter